📰 Human Use News
Page 127 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
July 22, 2022
BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announc...
July 22, 2022
Vabysmo (faricimab) simultaneously targets and inhibits two disease pathways that drive neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME)The CHMP recommendation
July 22, 2022
DGAP-News: Moderna, Inc. / Key word(s): Miscellaneous EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union 22.07.2022 / 14:05 The issuer is solely responsible for the content of this announceme...
July 22, 2022
By Dean Seal Moderna Inc. said Friday that the European Medicines Agency is formally recommending the use of the companys Covid-19 booster shot for adolescents in the European Union. The...
July 22, 2022
FOSTER CITY (dpa-AFX) - The Committee for Medicinal Products for Human Use or CHMP of the European Commission adopted a positive opinion recommending Veklury (Remdesivir) receive full marketing
July 22, 2022
Positive Opinion Based on HELIOS-A Phase 3 Study European Commission Decision Expected in September 2022 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today
July 21, 2022
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
July 21, 2022
- Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication - - Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 - NEWTON, Mass.andFLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharm...
July 20, 2022
First and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies1Extende...
July 20, 2022
/PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat...